Delcath Systems (DCTH) revenue breakdown
By product, HEPZATO KIT is the largest at 92% of fiscal 2025 revenue, growing 144% a year over 1 years.
By region, U.S. is the largest at 92% of fiscal 2025 revenue, growing 144% a year over 1 years.
Revenue by product
Fiscal years, as Delcath Systems reports them in its 10-K filings; fiscal 2025 total $85M.
| Products | 2021 | 2022 | 2024 | 2025 | Share |
|---|---|---|---|---|---|
| HEPZATO KIT | — | — | $32M | $79M | 92% |
| CHEMOSAT | — | — | $5M | $6M | 8% |
| Product revenue | $1M | $3M | — | — | — |
| Other revenue | $2M | $171,000 | — | — | — |
Revenue by region
Fiscal years, as Delcath Systems reports them in its 10-K filings; fiscal 2025 total $85M.
| Regions | 2024 | 2025 | Share |
|---|---|---|---|
| U.S. | $32M | $79M | 92% |
| Foreign | $5M | $6M | 8% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for DCTH.
Open DCTH in InvestinglyQuestions
Where does Delcath Systems make its money?
In fiscal 2025, by product: HEPZATO KIT $79M, CHEMOSAT $6M.
From Delcath Systems's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.